Author

Bethany Michelle Slifko

Observed names: B. Slifko, Bethany M. Slifko, Bethany Slifko

OpenAlex ID: A5083871054

Use of molecular NGS vs single gene testing differs by clinical setting and physician’s specialty in mNSCLC management.

2023 · Katherine Elizabeth Keating, Rachael Victoria Hewitt, et al. · Journal of Clinical Oncology · 1

Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

2022 · Linda B. Baughn, Elizabeth S. Mearns, et al. · Blood · 1

Impact of a real-time targeted expert outreach model on conversion of biomarker results to precision treatments.

2026 · Ying Liu, Helen Sadik, et al. · Journal of Clinical Oncology

2010P Impact of molecular test result report and its turnaround time (TAT) on patient's access to personalized therapy in advanced non-small cell lung cancer (aNSCLC): A comparative study between Italy and the UK

2025 · T.P. Sandberg, A-C. Nickel, et al. · Annals of Oncology

Analysis of data-driven physician engagement and effects on patient recruitment for clinical trial targeting rare gene mutations.

2025 · Ying Liu, Priscila Daniele Ramos Cirillo, et al. · Journal of Clinical Oncology

Effect of real-time data-driven physician engagement on appropriate precision oncology testing.

2024 · Ying Liu, Howard L. McLeod, et al. · Journal of Clinical Oncology

NTRK positivity and conversion to appropriate personalized treatment.

2024 · Bethany Michelle Slifko, Howard L. McLeod, et al. · Journal of Clinical Oncology

TP53 in Acute Myeloid Leukemia: Evolving from Just Another Prognostic Marker to an Actionable Biomarker Informing Treatment

2020 · Peter Riccelli, Marieke Hoefsmit, et al. · Blood

Works count: 8

Citation count: 2

H-index: 1

I10-index: